CytoSorbents Corporation (CTSO) Fundamentals

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend and others. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending. Geographically it derives substantial revenue from product sales in Germany.
SHARE INFORMATION
Market Cap$ 88,462,181
Shares Outstanding43,157,879
Float42,589,181
Percent Float97.73%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 40,108,567
Latest Fiscal EPS$ -0.58
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions211
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months1,654,124
Institutional Holdings Percent60.2%
Institutional Sold Previous 3 Months4,503,015
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months64,597
Insider Holdings Percent46.2
Insider Sold Previous 3 Months-
Insider Shares Owned20,115,862
TRADING INFO
52 Week High$ 9.80
52 Week Low$ 1.69
52 Week High Change$ -72.90
21 Day Moving Average$ 2.0695
21 Day Extended Moving Average$ 2.0267
50 Day Moving Average$ 2.1258
50 Day Extended Moving Average$ 2.1315
200 Day Moving Average$ 3.2626
200 Day Extended Moving Average$ 3.421
10 Day Average Volume291,371
20 Day Average Volume192,515
30 Day Average Volume154,391
50 Day Average Volume274,513
Alpha-0.003410
Beta0.3628
Standard Deviation0.163630
R20.012295
7 Day Price Change$ 0.06
7 Day Percent Change3.05%
21 Day Price Change$ -0.26
21 Day Percent Change-11.35%
30 Day Price Change$ -0.13
30 Day Percent Change-6.02%
Month to Date Price Change$ -0.25
Month to Date Percent Change-10.96%
Quarter to Date Price Change$ -0.16
Quarter to Date Percent Change-7.31%
180 Day Price Change$ -1.75
180 Day Percent Change-46.3%
200 Day Price Change$ -1.46
200 Day Percent Change-41.83%
Year to Date Price Change$ -2.16
Year to Date Percent Change-51.55%

CytoSorbents Corporation (CTSO) Key Ratios

PROFITABILITY
EBIT Margin-91.9%
EBITDA Margin-87.7%
Pre-Tax Profit Margin-76.2%
Profit Margin Count-91.55%
Gross Margin66.3%
Profit Margin TOT-91.55%
INCOME STATEMENTS
Revenue$ 33,854,953
Revenue Per Share$ 0.7844
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book1.70
Total Debt To Equity0.30
Int Coverage-2,575.50
Current Ratio3.90
Leverage Ratio1.40
Quick Ratio3.30
Long Term Debt To Capital0.22
VALUATION MEASURES
PE Ratio-2.20
Enterprise Value$ 61,784,071
Price to Sales2.5878
Price to Free Cash-2.30
PE High Last 5 Years-14.70
Price To Book1.70
Price To Cash Flow0.00
PE Low Last 5 Years-21.50
Price to Tangible Book1.70
MANAGEMENT EFFECTIVENESS
Receivables Turnover6.70
Invoice Turnover2.80
Assets Turnover0.40
Return Assets-45.02
Return on Equity-62.77
Return on Capital-47.90

CytoSorbents Corporation (CTSO) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorWithumSmith+Brown, PC
CEOPhillip P. Chan
Emplyoees221
Last AuditUQ
CIK0001175151
IndustryMedical Devices & Instruments
SectorHealthcare
NAICSMedical Laboratories(621511)
CONTACT INFO
Address7 Deer Park Drive
Suite K
Monmouth Junction, NJ 8852
Websitehttps://www.cytosorbents.com
Facsimile+1 732 329-8650
Telephone+1 732 329-8885
Emailavogel@cytosorbents.com


Your Recent History
NASDAQ
CTSO
CytoSorben..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.